Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Per Sandström

Showing results (111-120 of 140) with videos related to

Pageof 14
Sort By:
Cancer|February 10, 2024
Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE)Celestia S Higano, Sabina Dizdarevic, John Logue, et al.
Annals of Surgery Open : Perspectives of Surgical History, Education, and Clinical Approaches|September 23, 2024
Long-Term Follow-Up of Patients with Advanced Colorectal Liver Metastasis: A Survival Analysis from the Randomized Controlled Multicenter Trial LIGRODennis Björk, Kristina Hasselgren, Bård I Røsok, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 25, 2021
<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Ligand After <sup>223</sup>Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical ExperienceOliver Sartor, Christian la Fougère, Markus Essler, et al.
Surgery|January 14, 2017
Neoadjuvant chemotherapy does not affect future liver remnant growth and outcomes of associating liver partition and portal vein ligation for staged hepatectomyKristina Hasselgren, Massimo Malagò, Soumil Vyas, et al.
Prostate Cancer and Prostatic Diseases|February 22, 2022
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)Daniel J George, Neeraj Agarwal, Oliver Sartor, et al.
British Journal of Cancer|January 9, 2025
Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE studyJoe M O'Sullivan, Daniel Heinrich, Elena Castro, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|November 30, 2020
Minimally invasive versus open distal pancreatectomy: an individual patient data meta-analysis of two randomized controlled trialsMaarten Korrel, Frederique L Vissers, Jony van Hilst, et al.
BMC Surgery|July 18, 2025
Prospective evaluation of surgical treatment of liver metastasizing pancreatic cancer - ScanPan study protocolKristina Hasselgren, Caroline Williamsson, Johanna Wennerblom, et al.
Eclinicalmedicine|May 30, 2023
Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancerCelestia S Higano, Daniel J George, Neal D Shore, et al.
Annals of Surgery|May 5, 2018
10th Anniversary of ALPPS-Lessons Learned and quo VadisHauke Lang, Eduardo de Santibañes, Hans J Schlitt, et al.
Pageof 14

Showing results (111-120 of 140) with videos related to

Sort By:
Pageof 14
Cancer|February 10, 2024
Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE)Celestia S Higano, Sabina Dizdarevic, John Logue, et al.
Annals of Surgery Open : Perspectives of Surgical History, Education, and Clinical Approaches|September 23, 2024
Long-Term Follow-Up of Patients with Advanced Colorectal Liver Metastasis: A Survival Analysis from the Randomized Controlled Multicenter Trial LIGRODennis Björk, Kristina Hasselgren, Bård I Røsok, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 25, 2021
<sup>177</sup>Lu-Prostate-Specific Membrane Antigen Ligand After <sup>223</sup>Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical ExperienceOliver Sartor, Christian la Fougère, Markus Essler, et al.
Surgery|January 14, 2017
Neoadjuvant chemotherapy does not affect future liver remnant growth and outcomes of associating liver partition and portal vein ligation for staged hepatectomyKristina Hasselgren, Massimo Malagò, Soumil Vyas, et al.
Prostate Cancer and Prostatic Diseases|February 22, 2022
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)Daniel J George, Neeraj Agarwal, Oliver Sartor, et al.
British Journal of Cancer|January 9, 2025
Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE studyJoe M O'Sullivan, Daniel Heinrich, Elena Castro, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|November 30, 2020
Minimally invasive versus open distal pancreatectomy: an individual patient data meta-analysis of two randomized controlled trialsMaarten Korrel, Frederique L Vissers, Jony van Hilst, et al.
BMC Surgery|July 18, 2025
Prospective evaluation of surgical treatment of liver metastasizing pancreatic cancer - ScanPan study protocolKristina Hasselgren, Caroline Williamsson, Johanna Wennerblom, et al.
Eclinicalmedicine|May 30, 2023
Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancerCelestia S Higano, Daniel J George, Neal D Shore, et al.
Annals of Surgery|May 5, 2018
10th Anniversary of ALPPS-Lessons Learned and quo VadisHauke Lang, Eduardo de Santibañes, Hans J Schlitt, et al.
Pageof 14